SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-027199
Filing Date
2024-03-28
Accepted
2024-03-28 16:05:43
Documents
14
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202827-8k_tff.htm   iXBRL 8-K 26319
2 PRESS RELEASE DATED MARCH 28, 2024 REGARDING THE REGISTRANT'S FINANCIAL RESULTS ea020282701ex99-1_tff.htm EX-99.1 61400
  Complete submission text file 0001213900-24-027199.txt   273045

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tffp-20240328.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tffp-20240328_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tffp-20240328_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0202827-8k_tff_htm.xml XML 3718
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 24798802
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)